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Men are less prone to autoimmunity 
than women thanks to the anti-inflam-
matory effect of male sex hormones. 
But how these androgens, such as testos-
terone, exert this effect was a mystery. 
Dunn and colleagues now report on 
page  321 that a nuclear hormone re-
ceptor that gets boosted by testosterone 
switches off pro-inflammatory cytokine 
production in male CD4+ T cells.
Androgens are known to shift the 
balance from pro-inflammatory Th1 
cytokines to anti-inflammatory Th2 cyto-
kines. Thus, a testosterone shot is all it 
takes to suppress lupus and diabetes 
symptoms in mice. “The link between 
androgens and protection against auto-
immunity could not be clearer,” says senior 
author Larry Steinman. “But we still had 
to figure out how androgens actually 
  instruct T cells to stop attacking the host.”
A good candidate was the nuclear 
hormone receptor peroxisome proliferator 
activated receptor (PPAR)-α. Expres-
sion of PPAR-α was previously shown 
to increase in response to testosterone 
and to be higher in male compared 
with female hepatocytes. The team 
now shows that this gender difference 
extends to T cells and that it affects 
their inflammatory activities.
The group tested mice with experi-
mental autoimmune encephalitis (EAE), a 
mouse model of multiple sclerosis (MS). 
In the male mice, knocking out PPAR-α 
increased disease severity and expression 
of pro-inflammatory IFNγ and TNF by 
CD4+ T cells. In females, EAE was severe 
and cytokine production high in both 
wild-type and PPAR-α knock-outs.
The team showed that PPAR-α 
suppresses the production of IFNγ and 
TNF by preventing transcription factors 
NF-κB and c-Fos from binding to the 
promoters of these cytokine genes.
Steinman’s group is now examin-
ing PPAR-α expression in humans. If 
PPAR-α does show a gender-depen-
dent dichotomy in people, they plan 
to test a known PPAR-α agonist along 
with androgen therapy in clinical trials 
for MS. 
Receptors against autoimmunity
Tumor-free heart repair
Tissue regeneration without tumor formation may soon be within reach, at least for heart repair. 
On page 405, Behfar et al. report that embryonic stem (ES) cells preprogrammed to mature 
into cardiomyocytes can fix injured hearts in vivo without seeding tumors.
Directing ES cells to become a particular tissue type in vivo is an inefficient process. 
Consequently, transplanted ES cell populations may give rise to tumors in recipient hosts. 
Behfar et al. reasoned that delivery of partially differentiated ES cells may result in safe outcome 
provided that a modulator of differentiation shuts down troublesome tumor pathways.
When ES cells are delivered in vivo, their tumorigenicity is reduced in mice that suffer 
heart attacks. This is associated with TNF production. But TNF had not been tested for its 
ability to direct cardiomyocyte differentiation, although ES cells do express receptors for TNF. 
So the authors wondered whether TNF-driven signaling would be enough to guide cells into a 
differentiation pathway and thus prevent tumors in ES cell recipient mice.
The team engineered mice to express high levels of TNF in their hearts, and found that the 
transfer of undifferentiated ES cells did not lead to tumor formation. When ES cells were treated 
with TNF-induced supernatants in vitro, they not only expressed genes necessary for heart 
function but also down-regulated oncogenes as they differentiated into cardiac progenitor 
cells. In mice induced to suffer heart-attacks, these cells integrated into heart muscle, repaired 
scar tissue, and improved heart function.
TNF reduced the risk of tumor development by inducing the secretion of pro-cardiogenic 
factors including TGFβ. TGFβ also suppresses host immunity and may therefore reduce the 
likelihood of rejection of ES-derived cells. The effect of this immunosuppression on the 
weakened heart’s ability to fight infections is not yet clear, so the team plans to test 
autologous stem cells derived from the host’s own bone marrow. This option may remove 
the need for immunosuppression and improve the safety of stem cell therapy. 
Brain inflammation (blue) is more severe 
in the absence of the testosterone-
responsive receptor PPARα.
Tumors form in hearts injected 
with undifferentiated ES cells 
(top) but not when ES cells are 
predifferentiated (bottom).